Experts consider 'The Donald' effect and more in 2017 pharma predictions

10 January 2017

Excitement at opportunities, dread and doubts over what exactly the presidency of Donald Trump will mean for pharma all feature in predictions for the industry in 2017 expressed by an expert panel brought together by a pharma events organiser.

The CPhl Worldwide panel predicts pharma’s biggest opportunities and threats in 2017. Their predictions have been grouped together under three titles titled: The good, The bad and The Donald.

"Congress' path to repeal and replace the Affordable Care Act leads through a minefield"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK